Fetal brain mTOR signaling activation in tuberous sclerosis complex victoria tsai1

Cerebral Cortex

Volumn 24, Issue 2, 2014, Pages 315-327

  Parker, Whitney E ^a   Orlova, Ksenia A ^a   Baybis, Marianna ^a   Chi, Anthony W S ^a   Berg, Benjamin D ^a   Birnbaum, Jacqueline F ^a   Estevez, Jacqueline ^a   Okochi, Kei ^a   Sarnat, Harvey B ^b   Flores Sarnat, Laura ^b   Aronica, Eleonora ^c,d   Crino, Peter B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Epilepsy; Fetal tuber; Rapamycin; TSC2; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; RAPAMYCIN; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DEVELOPMENT; CELL SIZE; CELL VOLUME; CONTROLLED STUDY; ELECTROPORATION; EMBRYO DEVELOPMENT; FEMALE; FETUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; TUBEROUS SCLEROSIS;

EPILEPSY; FETAL TUBER; RAPAMYCIN; TSC2; TUBEROUS SCLEROSIS COMPLEX;

ADULT; ANIMALS; BRAIN; CELL MOVEMENT; CELL SIZE; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; MYELIN SHEATH; NEURAL STEM CELLS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84896320213     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhs310     Document Type: Article

References (54)

1. Anderl S, Freeland M, Kwiatkowski DJ, Goto J. 2011. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet. 20:4597-4604.
2. Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. 2005. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. Neuron. 45:207-221.
3. Bai J, Ramos RL, Ackman JB, Thomas AM, Lee RV, LoTurco JJ. 2003. RNAi reveals doublecortin is required for radial migration in rat neocortex. Nat Neurosci. 6:1277-1283.
4. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J et al. 2008. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 358:140-151.
5. Carson RP, Van Nielen DL, Winzenburger PA, Ess KC. 2012. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis. 45:369-380.
6. Chen B, Schaevitz LR, McConnell SK. 2005. Fezl regulates the differentiation and axon targeting of layer 5 subcortical projection neurons in cerebral cortex. Proc Natl Acad Sci USA. 102:17184-17189.
7. Chen CP, Su YN, Chang TY, Liu YP, Tsai FJ, Chen MR, Hwang JK, Chen TH, Wang W. 2010. Prenatal diagnosis of rhabdomyomas and cerebral tuberous sclerosis by magnetic resonance imaging in one fetus of a dizygotic twin pregnancy associated with a frameshift mutation in the TSC2 gene. Taiwan J Obstet Gynecol. 49:387-389.
8. Crino PB. 2010. The pathophysiology of tuberous sclerosis complex. Epilepsia. 51(Suppl 1):27-29.
9. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med. 355:1345-1356.
10. Cubelos B, Sebastian-Serrano A, Beccari L, Calcagnotto ME, Cisneros E, Kim S, Dopazo A, Alvarez-Dolado M, Redondo JM, Bovolenta P et al. 2010. Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. Neuron. 66:523-535.
11. DiMario FJ Jr. 2004. Brain abnormalities in tuberous sclerosis complex. J Child Neurol. 19:650-657.
12. Ess KC, Roach ES. 2012. New therapies for tuber-less sclerosis: white matter matters? Neurology. 78:520-521.
13. Feliciano DM, Su T, Lopez J, Platel JC, Bordey A. 2011. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest. 121:1596-1607.
14. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472-1487.
15. Garcia-Martinez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 416:375-385.
16. Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA et al. 2011. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA. 108:E1070-1079.
17. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12:9-22.
18. Hevner RF, Shi L, Justice N, Hsueh Y, Sheng M, Smiga S, Bulfone A, Goffinet AM, Campagnoni AT, Rubenstein JL. 2001. Tbr1 regulates differentiation of the preplate and layer 6. Neuron. 29:353-366.
19. Huang J, Dibble CC, Matsuzaki M, Manning BD. 2008. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 28:4104-4115.
20. Huang J, Manning BD. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 412:179-190.
21. Huang J, Wu S, Wu CL, Manning BD. 2009. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 69:6107-6114.
22. Jambaque I, Cusmai R, Curatolo P, Cortesi F, Perrot C, Dulac O. 1991. Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Dev Med Child Neurol. 33:698-705.
23. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. 2010. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 363:1801-1811.
24. Kwon CH, Zhu X, Zhang J, Baker SJ. 2003. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA. 100:12923-12928.
25. Kyin R, Hua Y, Baybis M, Scheithauer B, Kolson D, Uhlmann E, Gutmann D, Crino PB. 2001. Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. Am J Pathol. 159:1541-1554.
26. Levine D, Barnes PD, Madsen JR, Abbott J, Mehta T, Edelman RR. 1999. Central nervous system abnormalities assessed with prenatal magnetic resonance imaging. Obstet Gynecol. 94:1011-1019.
27. Magnitsky S, Walton RM, Wolfe JH, Poptani H. 2008. Magnetic resonance imaging detects differences in migration between primary and immortalized neural stem cells. Acad Radiol. 15:1269-1281.
28. Marcotte L, Aronica E, Baybis M, Crino PB. 2012. Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex. Acta Neuropathol. 123:685-693.
29. Marcotte L, Crino PB. 2006. The neurobiology of the tuberous sclerosis complex. Neuromol Med. 8:531-546.
30. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. 2008. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 28:5422-5432.
31. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. 2007. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 27:5546-5558.
32. Molyneaux BJ, Arlotta P, Hirata T, Hibi M, Macklis JD. 2005. Fezl is required for the birth and specification of corticospinal motor neurons. Neuron. 47:817-831.
33. Nguyen L, Besson A, Heng JI, Schuurmans C, Teboul L, Parras C, Philpott A, Roberts JM, Guillemot F. 2006. p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev. 20:1511-1524.
34. Nieto M, Monuki ES, Tang H, Imitola J, Haubst N, Khoury SJ, Cunningham J, Gotz M, Walsh CA. 2004. Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. J Comp Neurol. 479:168-180.
35. Orlova KA, Parker WE, Heuer GG, Tsai V, Yoon J, Baybis M, Fenning RS, Strauss K, Crino PB. 2010. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest. 120:1591-1602.
36. Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, Thom M, Strauss K, Aronica E, Storm PB, Crino PB. 2010. Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol. 69:850-863.
37. Park SH, Pepkowitz SH, Kerfoot C, De Rosa MJ, Poukens V, Wienecke R, DeClue JE, Vinters HV. 1997. Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study. Acta Neuropathol. 94:180-186.
38. Parker WE, Orlova KA, Heuer GG, Baybis M, Aronica E, Frost M, Wong M, Crino PB. 2011. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol. 178:296-305.
39. Ruegg S, Baybis M, Juul H, Dichter M, Crino PB. 2007. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res. 77:85-92.
40. Saito T. 2006. In vivo electroporation in the embryonic mouse central nervous system. Nat Protoc. 1:1552-1558.
41. Samuel-Abraham S, Leonard JN. 2010. Staying on message: design principles for controlling nonspecific responses to siRNA. FEBS J. 277:4828-4836.
42. Sparagana SP, Roach ES. 2000. Tuberous sclerosis complex. Curr Opin Neurol. 13:115-119.
43. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J et al. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 1:524-538.
44. Tillema JM, Leach JL, Krueger DA, Franz DN. 2012. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology. 78:526-531.
45. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH. 2002. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol. 52:285-296.
46. Wang Y, Greenwood JS, Calcagnotto ME, Kirsch HE, Barbaro NM, Baraban SC. 2007. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol. 61:139-152.
47. Way SW, McKenna J 3rd, Mietzsch U, Reith RM, Wu HC, Gambello MJ. 2009. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet. 18:1252-1265.
48. Way SW, Rozas NS, Wu HC, McKenna J 3rd, Reith RM, Hashmi SS, Dash PK, Gambello MJ. 2012. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet. 21:3226-3236.
49. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell. 124:471-484.
50. Yang Q, Inoki K, Kim E, Guan KL. 2006. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci USA. 103:6811-6816.
51. Zaroff CM, Barr WB, Carlson C, LaJoie J, Madhavan D, Miles DK, Nass R, Devinsky O. 2006. Mental retardation and relation to seizure and tuber burden in tuberous sclerosis complex. Seizure. 15:558-562.
52. Zeng LH, McDaniel S, Rensing NR, Wong M. 2010. Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword? Cell Cycle.. 9:2281-2285.
53. Zeng LH, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. 2011. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet. 20:445-454.
54. Zeng LH, Xu L, Gutmann DH, Wong M. 2008. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 63:444-453.